Approval was based on the combined results from five studies of adults with supraventricular tachycardia.
FDA Approves AOP Health’s Rapiblyk for Atrial Fibrillation and Atrial Flutter
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours